Resolute Capital Asset Partners LLC Buys 15,888 Shares of Lantheus Holdings, Inc. $LNTH

Resolute Capital Asset Partners LLC boosted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 13.1% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 136,900 shares of the medical equipment provider’s stock after acquiring an additional 15,888 shares during the quarter. Lantheus accounts for about 7.5% of Resolute Capital Asset Partners LLC’s portfolio, making the stock its 3rd biggest holding. Resolute Capital Asset Partners LLC owned 0.20% of Lantheus worth $13,361,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Signaturefd LLC grew its stake in Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 116 shares during the period. Hughes Financial Services LLC acquired a new stake in Lantheus in the 1st quarter valued at $81,000. UMB Bank n.a. grew its stake in Lantheus by 68.2% in the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock valued at $92,000 after acquiring an additional 381 shares during the period. Blue Trust Inc. grew its stake in Lantheus by 117.7% in the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 633 shares during the period. Finally, GAMMA Investing LLC grew its stake in Lantheus by 29.3% in the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock valued at $128,000 after acquiring an additional 298 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Down 1.6%

NASDAQ LNTH opened at $58.21 on Friday. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $118.21. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The business’s fifty day simple moving average is $71.48 and its 200-day simple moving average is $84.28. The firm has a market cap of $3.96 billion, a PE ratio of 15.48 and a beta of 0.14.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company had revenue of $378.05 million for the quarter, compared to analysts’ expectations of $389.69 million. During the same quarter in the prior year, the firm earned $1.80 EPS. The firm’s revenue was down 4.1% on a year-over-year basis. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of research reports. Wall Street Zen upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. William Blair restated a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. Truist Financial set a $63.00 price objective on Lantheus and gave the company a “hold” rating in a report on Monday, August 11th. Mizuho decreased their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. Finally, B. Riley decreased their price objective on Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a report on Monday, June 23rd. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $105.50.

Insider Buying and Selling

In related news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 26,066 shares of the firm’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director directly owned 318,650 shares of the company’s stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,838,066 shares of company stock valued at $384,430,031. 1.50% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.